New entities in 2022 WHO Classification of plasma cell disorders
Keywords:
Plasma cell disorders, cold agglutinin disease, monoclonal gammopathy of renal significance, TEMPI syndrome, AESOP syndromeAbstract
-
Downloads
References
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Oliveira Araujo IB, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720-48.
Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460-6.
Berentsen S, Barcellini W, D’Sa S, Randen U, Tvedt THA, Fattizzo B, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136:480-8.
Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122:1114-21.
Murakhovskaya I. Rituximab use in warm and cold autoimmune hemolytic anemia. J Clin Med. 2020;9:4034.
Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925-8.
Berentsen S, Randen U, Vågan AM, Hjorth-Hansen H, Vik A, Dalgaard J, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116:3180-4.
Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: Results of a Nordic prospective multicenter trial. Blood 2017;130:537-41.
Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D’Adda M, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: A phase 2 prospective GIMEMA study. Blood. 2018;132:547-50.
Röth A, Bommer M, Hüttmann A, Herich-Terhurne D, Kuklik N, Rekowski J, et al. Eculizumab in cold agglutinin disease (DECADE): An open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2:2543-9.
Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, et al. Inhibition of complement C1s in patients with cold agglutinin disease: Lessons learned from a named patient program. Blood Adv. 2020;4:997-1005.
Jalink M, Berentsen S, Castillo J, Treon SP, Cruijsen M, Fattizzo B, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021;138:2002-5.
Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45-59.
Gozzetti A, Guarnieri A, Zamagni E, Zakharova E, Coriu D, Bittrich M, et al. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. Am J Hematol. 2022;97:877-84.
Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87:698-711.
Klomjit N, Leung N, Fervenza F, Sethi S, Zand L. Rate and predictors of finding Monoclonal Gammopathy of Renal Significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol. 2020;31:2400-11.
Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122:3583-90.
Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021;96:846-53.
Sykes DB, O’Connell C, Schroyens W. The TEMPI syndrome. Blood. 2020;135:1199-203.
Sykes DB, Schroyens W, O’Connell C. The TEMPI syndrome-a novel multisystem disease. N Engl J Med. 2011;365:475-7.
Farooq U, Choudhary S, McLeod MP, Torchia D, Rongioletti F, Romanelli P, et al. Adenopathy and extensive skin patch overlying a Plasmacytoma (AESOP) Syndrome. J Clin Aesthet Dermatol 2012;5:25-7.
Rongioletti F, Romanelli P, Rebora A. Cutaneous mucinous angiomatosis as a presenting sign of bone plasmacytoma: a new case of (A)ESOP syndrome. J Am Acad Dermatol. 2006;55:909-10.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
